ESR1 and neoplasm: The researchers compared ctDNA with matched tumor tissue data and found that ESR1 mutations (0/81), (3/31), and (12/19) were present in tumor tissues collected at the initial diagnosis, before AI treatment, and after AI treatment progression, respectively.